Leukemia & Lymphoma, Volume 61, Issue 3 (2020)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 61, Issue 3 (2020)

See all volumes and issues
Vol 65, 2024 Vol 64, 2023 Vol 63, 2022 Vol 62, 2021 Volume 61, 2020 Vol 60, 2019 Vol 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Vol 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs

Commentaries

Article Commentary
iAMPlified gene expression offers new insights in B cell precursor leukemia subtype
Panagiotis Ntziachristos
Pages: 501-503
Published online: 03 Feb 2020
First Page PreviewforiAMPlified gene expression offers new insights in B cell precursor leukemia subtype | Full Text | References | PDF (412.5 KB) | EPUB
  • 101 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Non-transplant eligible multiple myeloma: deciphering optimal first line regimens
Iuliana Vaxman & Morie Gertz
Pages: 504-506
Published online: 24 Jan 2020
First Page PreviewforNon-transplant eligible multiple myeloma: deciphering optimal first line regimens | Full Text | References | PDF (408.1 KB) | EPUB
  • 215 Views
  • 0 CrossRef citations
  • 0Altmetric
Article Commentary
Sequence matters: elotuzumab more effective if used before daratumumab
Roger N. Pearse
Pages: 507-509
Published online: 17 Dec 2019
First Page PreviewforSequence matters: elotuzumab more effective if used before daratumumab | Full Text | References | PDF (301.1 KB) | EPUB
  • 529 Views
  • 0 CrossRef citations
  • 0Altmetric

Reviews

Review
The role of MYC in the transformation and aggressiveness of ‘indolent’ B-cell malignancies
Daniel Filip & Marek Mraz
Pages: 510-524
Published online: 20 Oct 2019
AbstractforThe role of MYC in the transformation and aggressiveness of ‘indolent’ B-cell malignancies | Full Text | References | PDF (1.7 MB) | EPUB
  • 1012 Views
  • 22 CrossRef citations
  • 0Altmetric
Review
Changing landscape of frontline therapy in chronic lymphocytic leukemia
Seema A. Bhat & Jennifer A. Woyach
Pages: 525-535
Published online: 15 Nov 2019
AbstractforChanging landscape of frontline therapy in chronic lymphocytic leukemia | Full Text | References | PDF (837.5 KB) | EPUB
  • 268 Views
  • 2 CrossRef citations
  • 0Altmetric
Review
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks
Matteo Molica, Massimo Breccia, Saveria Capria, Silvia Trisolini, Roberto Foa, Elias Jabbour & Tapan Mahendra Kadia
Pages: 536-545
Published online: 22 Nov 2019
AbstractforThe role of cladribine in acute myeloid leukemia: an old drug up to new tricks | Full Text | References | PDF (768.5 KB) | EPUB
  • 402 Views
  • 8 CrossRef citations
  • 0Altmetric

Original Articles

Article
Pediatric hodgkin lymphoma: disparities in survival by race
Karishma Khullar, Zorimar Rivera-Núñez, Sachin R. Jhawar, Richard Drachtman, Peter D. Cole, Bradford S. Hoppe & Rahul R. Parikh
Pages: 546-556
Published online: 23 Oct 2019
AbstractforPediatric hodgkin lymphoma: disparities in survival by race | Full Text | References | PDF (1.4 MB) | EPUB | Supplemental
  • 286 Views
  • 6 CrossRef citations
  • 0Altmetric
Article
Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017
Rudolf Weide, Stefan Feiten, Geothy Chakupurakal, Vera Friesenhahn, Kristina Kleboth, Hubert Köppler, Julia Lutschkin, Christoph van Roye, Jörg Thomalla & Jochen Heymanns
Pages: 557-566
Published online: 04 Nov 2019
AbstractforSurvival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017 | Full Text | References | PDF (1 MB) | EPUB
  • 6435 Views
  • 17 CrossRef citations
  • 0Altmetric
Open Access
Article
STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas
Roberto Tamma, Giuseppe Ingravallo, Francesco Gaudio, Tiziana Annese, Francesco Albano, Simona Ruggieri, Michele Dicataldo, Eugenio Maiorano, Giorgina Specchia & Domenico Ribatti
Pages: 567-574
Published online: 17 Oct 2019
AbstractforSTAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas | Full Text | References | PDF (1.9 MB) | EPUB
  • 329 Views
  • 16 CrossRef citations
  • 0Altmetric
Article
Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution
María Queralt Salas, Santiago Mercadal, Eva Domingo Domenech, Ana Carla Oliveira, Maite Encuentra, Fina Climent, Marcio Andrade Campos, Carmen Aguilera, Alberto Fernández de Sevilla, Anna Sureda & Eva González-Barca
Pages: 575-581
Published online: 05 Nov 2019
AbstractforValidation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution | Full Text | References | PDF (804.2 KB) | EPUB | Supplemental
  • 339 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Colonic mucosa-associated lymphoid tissue lymphoma: a case series
Jenny Tannoury, Aurélien Amiot, François Lemonnier, Jehan Dupuis, Charlotte Gagnière, Karim Belhadj, Fabien Le Bras, Iradj Sobhani, Corinne Haioun, Christiane Copie-Bergman & Michaël Lévy
Pages: 582-587
Published online: 06 Nov 2019
AbstractforColonic mucosa-associated lymphoid tissue lymphoma: a case series | Full Text | References | PDF (799.6 KB) | EPUB
  • 239 Views
  • 7 CrossRef citations
  • 0Altmetric
Article
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)
Agnieszka Pluta, Tadeusz Robak, Kamil Brzozowski, Konrad Stepka, Ewa Wawrzyniak, Anna Krawczynska, Magdalena Czemerska, Anna Szmigielska-Kaplon, Olga Grzybowska-Izydorczyk, Mateusz Nowicki, Piotr Stelmach, Marta Kuydowicz, Tomasz Gromek, Marek Hus, Grzegorz Helbig, Sebastian Grosicki, Ewa Bodzenta, Małgorzata Razny, Karol Wojcik, Lukasz Bolkun, Janusz Kloczko, Wanda Knopinska-Posluszny, Agnieszka Piekarska, Andrzej Hellman, Marta Sobas, Tomasz Wrobel, Elzbieta Patkowska, Ewa Lech-Maranda, Krzysztof Warzocha, Jerzy Holowiecki, Sebastian Giebel & Agnieszka Wierzbowska
Pages: 588-603
Published online: 29 Oct 2019
AbstractforEarly induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG) | Full Text | References | PDF (2 MB) | EPUB
  • 333 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia
Ingegerd Ivanov Öfverholm, Vasilios Zachariadis, Fulya Taylan, Yanara Marincevic-Zuniga, Anh Nhi Tran, Leonie Saft, Daniel Nilsson, Ann-Christine Syvänen, Gudmar Lönnerholm, Arja Harila-Saari, Magnus Nordenskjöld, Mats Heyman, Ann Nordgren, Jessica Nordlund & Gisela Barbany
Pages: 604-613
Published online: 22 Oct 2019
AbstractforOverexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia | Full Text | References | PDF (2.6 MB) | EPUB | Supplemental
  • 2716 Views
  • 5 CrossRef citations
  • 0Altmetric
Open Access
Article
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
Benjamin A. Derman, Mitchell Streck, Joseph Wynne, Trevor N. Christ, Emily Curran, Wendy Stock & Randall W. Knoebel
Pages: 614-622
Published online: 04 Nov 2019
AbstractforEfficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia | Full Text | References | PDF (1.1 MB) | EPUB | Supplemental
  • 689 Views
  • 25 CrossRef citations
  • 0Altmetric
Article
The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma
Yanchun Zhao, Yuanfei Shi, Huafei Shen, De Zhou, Li Li, Jingjing Zhu, Xiudi Yang, Yanlong Zheng, Lixia Zhu, Xiujin Ye & Wanzhuo Xie
Pages: 623-630
Published online: 06 Dec 2019
AbstractforThe prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma | Full Text | References | PDF (834.1 KB) | EPUB
  • 270 Views
  • 9 CrossRef citations
  • 0Altmetric
Article
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
Jonathan E. Kolitz, Stephen A. Strickland, Jorge E. Cortes, Donna Hogge, Jeffrey E. Lancet, Stuart L. Goldberg, Kathleen F. Villa, Robert J. Ryan, Michael Chiarella, Arthur C. Louie, Ellen K. Ritchie & Robert K. Stuart
Pages: 631-640
Published online: 25 Nov 2019
AbstractforConsolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia | Full Text | References | PDF (869.8 KB) | EPUB
  • 4645 Views
  • 10 CrossRef citations
  • 0Altmetric
Open Access
Article
Prognostic value of hypoalbuminemia at diagnosis in de novo non-M3 acute myeloid leukemia
Na Wang, Aakash Desai, Bei Ge, Wenya Li, Xianghong Jin, Hongzhao Bai, Kang Yu & Haige Ye
Pages: 641-649
Published online: 13 Nov 2019
AbstractforPrognostic value of hypoalbuminemia at diagnosis in de novo non-M3 acute myeloid leukemia | Full Text | References | PDF (1.2 MB) | EPUB | Supplemental
  • 185 Views
  • 9 CrossRef citations
  • 0Altmetric
Article
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Neil P. Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah Larson, Susanne Saussele, Delphine Rea, François-Xavier Mahon, Moshe Yair Levy, María Teresa Gómez-Casares, Fabrizio Pane, Franck-Emmanuel Nicolini, Michael J. Mauro, Oumar Sy, Patricia Martin-Regueira & Jeffrey H. Lipton
Pages: 650-659
Published online: 24 Oct 2019
AbstractforDasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study | Full Text | References | PDF (1.5 MB) | EPUB | Supplemental
  • 7003 Views
  • 83 CrossRef citations
  • 0Altmetric
Open Access
Article
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis
Douglas Tremblay, Amber King, Lihua Li, Erin Moshier, Alexander Coltoff, Anita Koshy, Marina Kremyanskaya, Ronald Hoffman, Michael J. Mauro, Raajit K. Rampal & John Mascarenhas
Pages: 660-667
Published online: 12 Nov 2019
AbstractforRisk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis | Full Text | References | PDF (771.7 KB) | EPUB | Supplemental
  • 563 Views
  • 16 CrossRef citations
  • 0Altmetric
Article
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis
Karthik Ramasamy, Sujith Dhanasiri, Howard Thom, Vanessa Buchanan, Suzanne Robinson, Vijay K. D’Souza & Katja Weisel
Pages: 668-679
Published online: 11 Nov 2019
AbstractforRelative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis | Full Text | References | PDF (1.6 MB) | EPUB | Supplemental
  • 5078 Views
  • 5 CrossRef citations
  • 0Altmetric
Open Access
Article
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
Maria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, Pieter Sonneveld, Meletios A. Dimopoulos, Bart Heeg, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam & Jianming He
Pages: 680-690
Published online: 05 Nov 2019
AbstractforThe effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison | Full Text | References | PDF (2 MB) | EPUB
  • 421 Views
  • 7 CrossRef citations
  • 0Altmetric
Article
Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
Emily Hoylman, Anna Brown, Anthony J. Perissinotti, Bernard L. Marini, Matthew Pianko, Jing Christine Ye, Erica Campagnaro & Victoria R. Nachar
Pages: 691-698
Published online: 18 Nov 2019
AbstractforOptimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma | Full Text | References | PDF (981.1 KB) | EPUB
  • 2362 Views
  • 11 CrossRef citations
  • 0Altmetric
Article
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium
Elżbieta Iskierka-Jażdżewska, Federico Canzian, Anna Stępień, Alessandro Martino, Daniele Campa, Angelica Stein, Małgorzata Krawczyk-Kuliś, Malwina Rybicka-Ramos, Sławomira Kyrcz-Krzemień, Aleksandra Butrym, Grzegorz Mazur, Artur Jurczyszyn, Daria Zawirska, Norbert Grząśko, Waldemar Tomczak, Edyta Subocz, Marzena Wątek, Marcin Pasiarski, Marcin Rymko, Małgorzata Całbecka, Agnieszka Druzd-Sitek, Jan Walewski, Marcin Kruszewski, Małgorzata Raźny, Jan Maciej Zaucha, Marek Dudziński, Paweł Gaj, Tadeusz Robak, Krzysztof Warzocha & Krzysztof Jamroziak
Pages: 699-706
Published online: 20 Nov 2019
AbstractforCereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium | Full Text | References | PDF (953.2 KB) | EPUB | Supplemental
  • 459 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Prediction of bortezomib-induced peripheral neuropathy with the R–R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study
Uta Nishiwaki, Taiji Yokote, Jun Hatooka, Takuji Miyoshi, Kazuki Iwaki, Yuki Masuda, Mayumi Fujimoto, Mitsuya Ueda, Yuki Kinoshita, Yui Arita, Masatomo Shimizu, Tomoyuki Yamada, Kazuki Tanabe, Toshikazu Akioka & Akihisa Imagawa
Pages: 707-713
Published online: 23 Oct 2019
AbstractforPrediction of bortezomib-induced peripheral neuropathy with the R–R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study | Full Text | References | PDF (647.7 KB) | EPUB
  • 190 Views
  • 1 CrossRef citations
  • 0Altmetric
Article
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)
Meletios A. Dimopoulos, Michele Cavo, Maria-Victoria Mateos, Thierry Facon, Bart Heeg, Sophie van Beekhuizen, Samron B. Gebregergish, Sandhya Nair, Marta Pisini, Annette Lam & Mary Slavcev
Pages: 714-720
Published online: 05 Nov 2019
AbstractforA matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT) | Full Text | References | PDF (1.2 MB) | EPUB
  • 803 Views
  • 3 CrossRef citations
  • 0Altmetric
Article
Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status
Matthew Harwood, Nathan Dunn, Julie Moore, Peter Mollee & Greg Hapgood
Pages: 721-727
Published online: 14 Nov 2019
AbstractforTrends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status | Full Text | References | PDF (984.6 KB) | EPUB
  • 249 Views
  • 3 CrossRef citations
  • 0Altmetric

Letters to the Editor

Letter
Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS
Adam S. Sperling, Matthew Leventhal, Christopher J. Gibson, Benjamin L. Ebert & David P. Steensma
Pages: 728-731
Published online: 12 Nov 2019
First Page PreviewforMyelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS | Full Text | References | PDF (609 KB) | EPUB
  • 367 Views
  • 4 CrossRef citations
  • 0Altmetric
Letter
Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma
Faye A. Sharpley, Faouzi Djebbari, Samih Fourali, Jaimal Kothari, John A. Lynes, Susan McLain-Smith & Karthik Ramasamy
Pages: 732-736
Published online: 27 Nov 2019
First Page PreviewforClinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma | Full Text | References | PDF (1,012.4 KB) | EPUB | Supplemental
  • 2312 Views
  • 3 CrossRef citations
  • 0Altmetric
Open Access
Letter
Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis
Marco Cerrano, Valérie Seegers, Emmanuel Raffoux, Florence Rabian, Marie Sébert, Raphael Itzykson, Virginie Lemiale, Lionel Adès, Nicolas Boissel, Hervé Dombret, Elie Azoulay & Etienne Lengliné
Pages: 737-740
Published online: 11 Nov 2019
First Page PreviewforPredictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis | Full Text | References | PDF (593 KB) | EPUB | Supplemental
  • 237 Views
  • 5 CrossRef citations
  • 0Altmetric
Letter
Inhibitors of fatty acid oxidation enhance death of acute myeloid leukemia cells lacking NIX or SQSTM1
Matthew Tcheng, Ishmael Samudio & Paul A. Spagnuolo
Pages: 741-744
Published online: 11 Nov 2019
First Page PreviewforInhibitors of fatty acid oxidation enhance death of acute myeloid leukemia cells lacking NIX or SQSTM1 | Full Text | References | PDF (941.4 KB) | EPUB
  • 138 Views
  • 0 CrossRef citations
  • 0Altmetric
Letter
Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia
Yoshimitsu Shimomura, Masahiko Hara, Hayato Maruoka, Tomohiro Yabushita & Takayuki Ishikawa
Pages: 745-748
Published online: 11 Nov 2019
First Page PreviewforMeasurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia | Full Text | References | PDF (546.1 KB) | EPUB | Supplemental
  • 148 Views
  • 1 CrossRef citations
  • 0Altmetric
Letter
B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax
Anna Christoforidou, Zoe Bezirgiannidou, George Vrachiolias, Menelaos Papoutselis, Emmanouil Spanoudakis & Ιoannis Kotsianidis
Pages: 749-752
Published online: 12 Nov 2019
First Page PreviewforB-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax | Full Text | References | PDF (762.8 KB) | EPUB
  • 223 Views
  • 4 CrossRef citations
  • 0Altmetric

Explore articles